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and lipid levels. Here we report the data from the Italian 
patients enrolled in the study.
Results Sixty-seven patients (mean age 50.4 years, 
61.2% male) have been enrolled and have received a mean 
45.4 ± 24.3 months of  Omnitrope®. A total of 55.2% of 
patients were reported to have experienced adverse events 
(AEs), including arthralgia, myalgia, abdominal distension 
and hypoaesthesia, and 4.5% had adverse drug reactions. 
Fourteen serious AEs have been recorded; none of these 
are considered related to the study drug. The effectiveness 
of  Omnitrope® was similar to other available somatropin 
preparations.
Conclusions This study confirms the effectiveness and 
safety of  Omnitrope® in adult patients with GHD in Italy. 
However, due to the limited size of the study population, 
Abstract 
Purpose To report the long-term effectiveness and safety 
of the recombinant human growth hormone  Omnitrope®, 
a somatropin biosimilar to  Genotropin®, in Italian patients 
with growth hormone deficiency (GHD) enrolled in the 
PATRO Adults study.
Methods The PATRO Adults study is an ongoing obser-
vational, longitudinal, non-interventional global post-mar-
keting surveillance study, conducted in several European 
countries. The primary endpoint is long-term safety; sec-
ondary endpoints include the effectiveness of  Omnitrope®, 
which was assessed using serum insulin-like growth fac-
tor-1 levels, body composition, bone mineral density 
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these results need to be further confirmed by the global 
PATRO Adults study.
Keywords Growth hormone deficiency · 
Hypopituitarism · Omnitrope® · Recombinant human 
growth hormone · Insulin-like growth factor-1 · Safety
Introduction
Adult-onset growth hormone deficiency (GHD) is a condi-
tion associated with abnormal substrate metabolism, body 
composition, and physical and psychosocial function, due 
to the inability of the pituitary gland to produce enough 
growth hormone (GH) [1]. Consequently, patients with 
adult-onset GHD have difficulties in controlling their body 
weight, show increased body fat (more specifically abdomi-
nal fat), and decreased muscle mass with reduced muscle 
strength and exercise capacity. Increased anxiety levels and 
depressed mood also contribute to a reduced quality of life 
in these patients. Adult-onset GHD can result from hypo-
thalamic-pituitary disease, neurosurgery and/or cranial irra-
diation during the treatment of pituitary and brain tumours, 
or traumatic brain injuries [2].
Guidelines for the diagnosis and treatment of adults 
with GHD recommend replacement therapy with recombi-
nant human GH (rhGH), which is dosed based on plasma 
insulin-like growth factor-1 (IGF-1) levels and the presence 
or absence of side effects [1, 3]. Replacement therapy has 
been shown to correct the metabolic, functional and psy-
chological abnormalities associated with adult GHD [4]. 
Lipolysis is increased in response to rhGH replacement 
therapy, resulting in a reduction of total body (mainly vis-
ceral) fat, while one year of rhGH therapy seems to reduce 
early cardiac organ damage in adult patients with GHD [5]. 
It has also been suggested that exercise capacity and physi-
cal performance can be improved by this treatment [1, 3].
One rhGH available for the treatment of GHD in adults 
is  Omnitrope® (Sandoz, Kundl, Austria).  Omnitrope®, 
expressed by a transformed strain of Escherichia coli, is 
biosimilar to Genotropin® (Pfizer Limited, Sandwich, UK) 
and was the first product to be approved by the European 
Medicines Agency (EMA) in 2006 using the European bio-
similar regulatory pathway [6].
In adults,  Omnitrope® is approved for the replacement 
of adult- or childhood-onset GHD. Studies in adult patients 
suggest that switching from  Genotropin® to  Omnitrope® 
has no impact on the safety and efficacy profile [7, 8]; how-
ever, data assessing the long-term safety and effectiveness 
of  Omnitrope® in adults in the setting of routine clinical 
practice are not yet available. To address this, the PAtients 
TReated with  Omnitrope® (PATRO) Adults study was initi-
ated as part of the Omnitrope® Active Pharmacovigilance 
Program agreed with the EMA upon the approval of 
 Omnitrope®. PATRO Adults is a long-term post-marketing 
surveillance (PMS) study investigating the long-term safety 
and effectiveness of  Omnitrope® in adults with GHD. It is 
being conducted as part of the Risk Management Plan for 
 Omnitrope®, to fulfil the commitment with the EMA [9]. 
Preliminary results of this study indicate that  Omnitrope® is 
well tolerated in routine clinical practice [10–12]. Between 
September 2007 and September 2015, 954 patients from 
eight different countries (Czech Republic, France, Ger-
many, Italy, Spain, Sweden, The Netherlands, and UK) 
were enrolled in the PATRO Adults study. Here we report 
the results of all patients enrolled in Italy.
Materials and methods
Study design
PATRO Adults is a multicentre, open-label, longitudinal, 
non-interventional PMS study, which was initiated in Sep-
tember 2007 and is being conducted in hospitals and spe-
cialised endocrinology centres in various countries where 
 Omnitrope® is approved and regularly prescribed. The 
design and methods of this study have been published in 
detail previously [9]. Briefly, eligible patients are adults 
(≥15 years old) receiving treatment with Omnitrope® for 
GHD (isolated or combined with other hormone deficien-
cies) and who provided written informed consent. Patients 
who had received a previous rhGH were also eligible for 
inclusion. The study was reviewed and approved by each 
study site’s Independent Ethics Committee or Institutional 
Review Board before the starting and was conducted in 
accordance with the Declaration of Helsinki.
Treatment and outcomes
Patients included in the PATRO Adults study received 
 Omnitrope® treatment in accordance with the recommenda-
tions in the Summary of Product Characteristics [13] and/or 
the prescribing information of the respective countries. The 
primary objective of this PMS study was to collect and ana-
lyse data on the long-term safety of  Omnitrope® in adults 
treated within routine clinical practice to extend the global 
safety database of  Omnitrope®. Aspects of clinical safety, 
such as risk of developing glucose intolerance or diabetes 
and occurrence of malignancies, were examined along with 
the effects on cardiovascular risk factors, such as blood 
pressure and inflammatory markers. All adverse events 
(AEs), serious adverse events (SAEs), adverse drug reac-
tions (ADRs), and serious adverse drug reactions (SADRs) 
were collected and recorded in electronic case report forms 
(e-CRF) and entered into the Sandoz Safety Database.
671J Endocrinol Invest (2017) 40:669–678 
1 3
The secondary objective was to monitor the treated pop-
ulation and to collect data on effectiveness issues related 
to  Omnitrope® treatment. These included measurements 
of IGF-1 levels within age-and gender-adjusted normal 
ranges, and the fasting lipid profile. Body composition 
assessment was carried out using anthropometric meas-
ures (weight, waist and hip circumferences, total fat mass, 
lean body mass and body mass index [BMI]). All evalua-
tions and assessments were performed at each local centre, 
according to the local practice.
Statistical analysis
The safety analysis set (SAF) included all patients who had 
documentation of any data in an e-CRF whilst the effec-
tiveness analysis set (EFF) included all patients who had 
at least one dose of  Omnitrope®. Statistical analyses for 
this study were performed using the software package SAS 
(version 9.3).
All AEs were coded using MedDRA version 17.1. Con-
comitant medication was coded according to WHO Drug 
Dictionary (version 14.3) and the medications were tabu-
lated by Anatomical Therapeutic Chemical term in their 
current version. For continuous/quantitative variables, 
descriptive statistics including the number of data values 
available, number of data values missing, arithmetic mean, 
standard deviation, minimum, median and maximum were 
calculated. When appropriate, continuous parameters were 
compared using t tests or Wilcoxon non-parametric tests. 
For categorical/qualitative variables, frequency and per-
centage tables were generated. When appropriate, categori-
cal data were compared using Chi-square or Fisher exact 
tests. Statistical tests were two sided at the significance 
level of 0.05.
Results
As of August 2015, 67 patients (mean age 50.4 years, 61.2% 
male) had been enrolled from eight sites in Italy (Table 1) 
and received a mean 45.4 ± 24.3 months of  Omnitrope® 
treatment. Of these, 15 patients (22.4%) had discontinued 
treatment at the time of analysis; reasons for discontinua-
tion included: patients did not wish to continue injections 
(n = 2; 13.3%), AEs (n = 1; 6.7%), referral to another endo-
crinologist (n = 1; 6.7%), non-compliance (n = 1; 6.7%) and 
loss to follow-up (n = 2; 13.3%). The reason for discontinu-
ation of  Omnitrope® was unknown in the remaining eight 
patients (53.3% of discontinued patients). Overall, 31.3% 
of patients had received another rhGH before  Omnitrope®. 
The mean duration of rhGH pre-treatment was 7.45 ± 4.97 
(range 1.6–17.3) years.
Table 1  Baseline characteristics and demographics of Italian patients 
enrolled in the PATRO Adults study as of August 2015
Characteristic N = 67
Gender, n (%)
 Male 41 (61.2)
 Female 26 (38.8)
Age, years 50.4 ± 14.5
Age group, n (%)
 <25 years 4 (6.0)
 25–65 years 56 (83.6)
 >65 years 7 (10.4)
BMI, kg/m2 28.9 ± 5.6
Hip circumference, cm 104.5 ± 18.3
Waist circumference, cm 94.6 ± 14.4
Diagnosis at presentation, n (%)
 Isolated GHD 9 (13.4)
 Combined GHD 58 (86.6)
Onset of puberty, n (%)a
 Normal 41 (61.2)
 Late 9 (13.4)
Onset of GHD
 Childhood onset 8 (11.9)
 Adulthood onset 59 (88.1)
Family history of GHD, n (%)
 No 43 (64.2)
 Unknown 24 (35.8)
Family history of diabetes, n (%)
 No 42 (62.7)
 Yes 9 (13.4)
 Unknown 16 (23.9)
Family history of autoimmune disease, n (%)
 No 44 (65.7)
 Yes 2 (3.0)
 Unknown 21 (31.3)
Family history of other relevant disease, n (%)
 No 30 (44.8)
 Yes 22 (32.8)
 Unknown 15 (22.4)
Previous treatment status, n (%)
 Treatment naïve 46 (68.7)
 Pre-treated 21 (31.3)
Concomitant medication for combined GHD patients
 Levothyroxine sodium 51 (87.9)
 Cortisone acetate 40 (69.0)
 Colecalciferol 28 (48.3)
 Testosterone 19 (32.8)
 Desmopressin acetate 15 (25.9)
 Testosterone undecanoate 13 (22.4)
 Acetylsalicylic acid 9 (15.5)
 Hydrocortisone 7 (12.1)
 Simvastatin 7 (12.1)
Omnitrope® dosing at baseline, mg/kg/day 0.22 ± 0.11
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Safety
As of August 2015, in the current Italian analysis, 89 
AEs had been reported in 37 (55.2%) of the 67 patients 
included in the SAF (Table  2). The most common AEs 
reported were arthralgia, asthenia and insomnia. A total 
of six suspected ADRs were reported in three (4.5%) 
patients and included two arthralgia, two myalgia events, 
one event of abdominal distension and one of hypoaes-
thesia. A total of 14 SAEs in 10 (14.9%) patients were 
reported; however, none were suspected to be related to 
the study drug. One patient developed a basal cell car-
cinoma after 2  years of rhGH replacement therapy, but 
this was not considered drug related and was completely 
cured. This was the only malignancy reported during the 
study.
Two patients developed diabetes mellitus during 
the course of the treatment; however, this was not con-
sidered a drug-related event. The mean level of glu-
cose (Fig.  1a) and glycosylated haemoglobin (HbA1c; 
Fig.  1b) remained unchanged throughout the study 
period.
Effectiveness
Body composition changed with  Omnitrope® treatment, 
with slight increases seen in most of the anthropometric 
parameters investigated over the treatment period; how-
ever, none of these were significant (Table 3).
There was no apparent change in lipid levels over 
the study duration. A slight decrease in low-density 
lipoprotein (LDL) cholesterol levels was observed over 
the duration of the study (Fig. 2a), whereas the ratio of 
high-density lipoprotein (HDL)/LDL cholesterol over 
time did not significantly change (Fig. 2b).
In the first 6 months of  Omnitrope® therapy, IGF-1 
values increased significantly from baseline in patients 
who had not received a previous rhGH (Fig. 3). Over the 
remainder of the study, IGF-1 values remained relatively 
stable (Fig. 3).
Discussion
The results of this interim analysis show that  Omnitrope® 
is well tolerated in Italian adults with GHD. The most 
common AEs reported were arthralgia, asthenia and 
insomnia, and SAEs were reported in 14.9% of patients. 
These safety data are consistent with the safety profile 
of  Omnitrope® observed in all patients included in the 
PATRO Adults study, which has been presented at inter-
national conferences in 2013, 2014 and 2015 [10–12]. 
These reports indicate that  Omnitrope® was well toler-
ated in real-life practice with no confirmed cases of drug-
related diabetes, reports of malignancy or other safety 
issues. The safety profile of  Omnitrope® is similar in both 
All values are presented as mean ± standard deviation unless other-
wise stated
BMI body mass index, GHD growth hormone deficiency, SD standard 
deviation
a Normal onset of puberty was considered 8–13 years of age in girls 
and 9–14 years of age in boys; late onset of puberty was consid-
ered >13 years of age in girls and >14 years of age in boys
Table 1  (continued)
Characteristic N = 67
Duration of  Omnitrope® treatment, months 45.4 ± 24.3
Table 2  Adverse events in the SAF (n = 67)
AEs adverse events, SAE serious adverse event
Events, n Patients, n (%)
Any AE 89 37 (55.2)
Relationship to study drug
 Not suspected 83 35 (52.2)
Intensity
 Mild 54 33 (49.3)
 Moderate 32 16 (23.9)
 Severe 3 3 (4.5)
Outcome
 Resolved completely 40 22 (32.8)
 Resolved with sequelae 3 3 (4.5)
 Ongoing 46 25 (37.3)
Medication given
 No 67 30 (44.8)
 Yes 21 17 (25.4)
 Missing 1 1 (1.5)
Changes to  Omnitrope®
 Not changed 76 33 (49.3)
 Reduced 3 2 (3.0)
 Interrupted 8 5 (7.5)
 Missing 2 1 (1.5)
SAE 14 10 (14.9)
AEs in ≥2 patients, n (%)
 Arthralgia – 6 (9.0)
 Asthenia – 5 (7.5)
 Insomnia – 4 (6.0)
 Headache – 3 (4.5)
 Back pain – 2 (3.0)
 Hypokalaemia – 2 (3.0)
 Muscle spasms – 2 (3.0)
 Myalgia – 2 (3.0)
 Osteopenia – 2 (3.0)
 Paraesthesia – 2 (3.0)
 Weight increased – 2 (3.0)
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adults naïve to rhGH and patients previously treated with 
other rhGH formulations.
The link between patients receiving replacement rhGH 
therapy and the possibility of developing diabetes has been 
a concern, with anecdotal reports of a cause and effect rela-
tionship. The incidence of metabolic syndrome is higher in 
patients with GHD compared with reference populations 
[14, 15]. However, there are conflicting reports regarding 
the effect of GH replacement on glucose metabolism. Some 
studies have shown that rhGH treatment may accelerate 
the onset of diabetes in predisposed paediatric individuals 
and patients receiving rhGH therapy may have an increased 
Fig. 1  Change in a fasting 
glucose and b glycosylated 
haemoglobin (HbA1c) in the 
total safety analysis set over the 
study period
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incidence of metabolic abnormalities in the long term 
[16–19]. Conversely, other authors have found no evidence 
to support an increase in the onset of diabetes mellitus in 
rhGH-treated patients [16, 20]. The results emerging from 
this analysis seem to confirm that no link exists between 
adequate rhGH replacement therapy in adults with GHD 
and the development of diabetes. In fact, no significant 
changes in glucose metabolism were recorded in the entire 
cohort of patients, while in the two cases that developed 
diabetes mellitus during the study, this was not considered 
drug-related.
Patients with GHD tend to have increased LDL and 
decreased HDL cholesterol levels, with both features con-
sidered characteristic of metabolic syndrome [3]. However, 
some studies have suggested that rhGH replacement ther-
apy may reverse this trend, increasing the level of HDL and 
decreasing the level of LDL [3]. Although the sample size 
is too small to be conclusive, in the Italian GHD population 
evaluated in the present study, there was a slight decrease 
in the level of LDL during treatment with  Omnitrope®.
As both GH and IGF-1 have mitogenic properties, there 
is concern that rhGH therapy could increase the risk of 
developing malignant diseases in treated patients. So far, 
there is no evidence from the Italian GHD patients included 
in the PATRO Adults study that rhGH therapy increases the 
risk of malignancy as only one case was reported, which 
was not thought to be drug related. These results are con-
sistent with several other studies, which also suggest that 
adequate replacement therapy with rhGH does not increase 
the risk of de novo or recurring tumours [21–25].
These results are also in line with other studies which 
explored the efficacy of  Omnitrope® [7, 8]. While the 
results of this analysis are supportive of those from the 
long-term interventional trials of rhGH for the treatment 
of adults with GHD, there are some limitations in the 
interpretation of these findings. The number of patients 
included in this interim analysis over the long term was 
small and unselected, which may bias the results. None-
theless, despite these limitations we believe that this 
study is reflective of real-world clinical practice in Italy 
and may be interpreted as such.
It is of interest to compare our findings with the data 
collected by the global PATRO Adults study [26]. The 
results of this analysis are consistent with the latest data 
of the overall PATRO Adults study, which was analysed 
in September 2015 (data on file). In the 954 patients 
recruited so far [mean (SD) age 50.2 (15.2) years; mean 
(SD) BMI 29.4 (6.1) kg/m2], 515 (54%) have been pre-
treated with another rhGH. Overall, 1497 AEs have been 
reported in 473 (49.6%) patients; 245 of these were con-
sidered serious. There were 110 ADRs in 68 patients, 
including 19 general disorders/administration site condi-
tions, 18 nervous system disorders, 16 musculoskeletal/
connective tissue disorders and two events of increased 
IGF-1 levels. A total of 23 SAEs in 16 patients were sus-
pected to be related to treatments, including one case 
Table 3  Change in body 
composition in the EFF
BMI body mass index, N number of patients
Anthro-
pometric 
parameter
Waist circumfer-
ence, cm
Lean body mass Total fat mass Weight, kg BMI, kg/m2
N Mean ± SD N Mean ± SD N Mean ± SD N Mean ± SD N Mean ± SD
Baseline 18 94.6 ± 14.4 9 57.55 ± 7.03 10 35.3 ± 9.4 46 80.4 ± 19.0 46 28.8 ± 5.7
0.5 years 7 98.8 ± 24.3 1 – 1 – 18 80.7 ± 23.5 15 27.9 ± 5.9
1.0 years 17 94.5 ± 15.4 5 63.9 ± 8.6 5 35.4 ± 7.5 36 78.1 ± 18.5 31 28.9 ± 5.4
1.5 years 14 97.8 ± 13.7 5 59.6 ± 5.8 7 36.1 ± 7.2 31 82.20 ± 23.1 25 29.0 ± 6.3
2.0 years 9 95.7 ± 9.4 0 – 0 – 30 76.9 ± 19.1 22 27.0 ± 4.4
2.5 years 6 89.7 ± 10.0 0 – 0 – 22 79.2 ± 18.3 17 28.1 ± 4.3
3.0 years 5 90.2 ± 9.7 1 – 2 40.9 ± 0.3 20 72.5 ± 11.7 14 26.6 ± 4.2
3.5 years 10 97.9 ± 14.1 3 65.2 ± 1.3 6 37.8 ± 6.3 18 76.9 ± 16.5 15 27.9 ± 4.0
4.0 years 6 105.5 ± 18.5 1 – 1 – 22 77.2 ± 16.2 21 27.5 ± 3.9
4.5 years 2 90.5 ± 2.1 0 – 0 – 15 72.4 ± 15.4 13 27.0 ± 4.7
5.0 years 4 94.5 ± 10.7 2 45.4 ± 34.5 3 39.1 ± 7.8 16 75.2 ± 11.7 14 27.3 ± 4.1
5.5 years 3 96.2 ± 5.8 1 – 4 37.6 ± 6.4 9 72.6 ± 12.6 8 27.2 ± 2.3
6.0 years 2 88.3 ± 4.6 1 – 2 38.5 ± 1.6 10 81.2 ± 13.5 9 29.3 ± 5.2
6.5 years 1 – 0 – 0 – 7 88.5 ± 12.0 7 26.2 ± 3.7
7.0 years 0 – 0 – 0 – 2 74.0 ± 14.6 2 27.7 ± 4.2
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each of: worsening of diabetes mellitus, dyspnoea and 
multiple endocrine neoplasia type 1. Of the 105 patients 
who discontinued treatment, 23 (21.9%) patients discon-
tinued due to an AE.
In conclusion, this preliminary analysis shows that, 
as with other rhGHs, treatment with  Omnitrope® is well 
tolerated in adult patients with GHD in routine clini-
cal practice, with no confirmed relationship with the 
Fig. 2  Change in a fasting 
high-density lipoprotein (HDL) 
cholesterol and fasting low-
density lipoprotein (LDL) cho-
lesterol and b the ratio of HDL 
cholesterol and LDL cholesterol 
in the total safety analysis set 
over the study period
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development of diabetes, no occurrence of malignancy 
or other additional safety issues. This analysis also con-
firms the effectiveness of  Omnitrope® for the treatment of 
adults with GHD.
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